Wed Feb 10 2021

“Long term prognostic value of suPAR in chronic heart failure: reclassification of patients with low MAGGIC score”, published in Clinical Chemistry and Laboratory Medicine

This brand-new study conducted at the French University Hospital of Montpellier, investigated the long-term prognostic value of suPAR and whether it adds information on chronic heart failure for patients at risk.

So far, the c-reactive protein (CRP) has been the most studied inflammatory biomarker with regards to chronic heart failure. However, several other biomarkers, such as suPAR, have emerged in recent years.

Demographics, as well as clinical and biological variables, were assessed in a total of 182 patients with chronic heart failure over a median follow-up period of 80 months. Inflammatory biomarkers (i.e., CRP, sST2, and suPAR) were performed.

The study found that the risk classification analysis was significantly improved with the addition of suPAR, particularly for short- and long-term mortality.

The authors also observed a favorable outcome associated with patients with a low MAGGIC score and a low suPAR level by comparison to patients with a low MAGGIC score but high suPAR values.

Out of the three observed biomarkers, only suPAR could be independently associated with 96-month mortality for patients with chronic heart failure.

Dupuy, A.M., et al. Clinical Chemistry and Laboratory Medicine, 2021

The authors concluded that among the three observed inflammatory biomarkers, only suPAR levels were independently associated with 96-month mortality for patients with chronic heart failure.

An algorithm based on clinical score, a cardiomyocyte stress biomarker and an inflammatory biomarker could help to a more reliable long term risk stratification in heart failure.

Find the study here

+800

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 38 hospitals

38 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling. This period covers October 1, 2021, until September 30, 2022.
Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates